Soleus Capital Management, L.P. Erasca, Inc. Transaction History
Soleus Capital Management, L.P.
- $1.18 Billion
- Q3 2024
A detailed history of Soleus Capital Management, L.P. transactions in Erasca, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 2,162,162 shares of ERAS stock, worth $3.96 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
2,162,162
Previous 2,162,162
-0.0%
Holding current value
$3.96 Million
Previous $5.1 Million
15.68%
% of portfolio
0.5%
Previous 0.52%
Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$35.5 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$30.8 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$29.7 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$25.2 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$24.3 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $224M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...